Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.35 +9.8%	$1.44	$0.65 ▼ $17.00	$22.96M	1.19	360,040 shs	2.12 million shs
IMCC IM Cannabis	$2.36 +8.0%	$2.81	$1.29 ▼ $7.12	$12.36M	2.2	45,923 shs	45,040 shs
TXMD TherapeuticsMD	$1.10 +1.8%	$1.14	$0.70 ▼ $2.44	$12.73M	0.42	18,952 shs	21,585 shs
VRAX Virax Biolabs Group	$0.77 +3.2%	$0.85	$0.72 ▼ $7.63	$3.32M	1.66	79,735 shs	17,641 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	0.00%	+1.50%	-19.16%	+92.03%	-90.92%
IMCC IM Cannabis	0.00%	-11.47%	-16.19%	+23.30%	-18.79%
TXMD TherapeuticsMD	0.00%	-5.98%	-7.57%	-24.14%	-37.86%
VRAX Virax Biolabs Group	0.00%	-0.65%	-22.64%	-25.00%	-85.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	2.588 of 5 stars	3.3	4.0	1.1	0.8	1.3
IMCC IM Cannabis	0.4916 of 5 stars	0.0	5.0	1.5	0.0	0.0
TXMD TherapeuticsMD	0.1463 of 5 stars	0.0	3.0	0.0	0.0	0.6
VRAX Virax Biolabs Group	3.2114 of 5 stars	3.5	5.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,825.93% Upside
IMCC IM Cannabis	0.00	N/A	N/A	N/A
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A
VRAX Virax Biolabs Group	3.00	Buy	$3.00	292.16% Upside

Current Analyst Ratings Breakdown

Latest VRAX, TXMD, IMCC, and CTXR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$10.25 per share	N/A
IMCC IM Cannabis	$39.44M	0.31	N/A	N/A	$1.03 per share	2.29
TXMD TherapeuticsMD	$1.76M	7.23	N/A	N/A	$2.37 per share	0.46
VRAX Virax Biolabs Group	$10K	332.01	N/A	N/A	$1.26 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.08	N/A	N/A	-60.03%	-33.83%	N/A
IMCC IM Cannabis	-$7.72M	-$0.54	N/A	N/A	N/A	-4.19%	-59.80%	-5.15%	11/12/2025 (Estimated)
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-17.94%	-2.01%	-1.40%	11/10/2025 (Estimated)
VRAX Virax Biolabs Group	-$6.06M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/1/2025 (Estimated)

Latest VRAX, TXMD, IMCC, and CTXR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	-$0.80	-$0.04	-$0.80	$1.92 million	$1.92 million
8/12/2025	Q2 2025	IMCC IM Cannabis	-$0.1367	-$0.0653	+$0.0714	-$0.07	$12.88 million	$9.21 million
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	$0.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.47	0.14
IMCC IM Cannabis	0.32	0.72	0.62
TXMD TherapeuticsMD	N/A	2.89	2.89
VRAX Virax Biolabs Group	N/A	7.27	7.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
IMCC IM Cannabis	7.68%
TXMD TherapeuticsMD	30.74%
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
IMCC IM Cannabis	N/A
TXMD TherapeuticsMD	2.30%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	17.01 million	15.19 million	Optionable
IMCC IM Cannabis	340	5.25 million	N/A	Not Optionable
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable
VRAX Virax Biolabs Group	5	4.34 million	2.38 million	Not Optionable

VRAX, TXMD, IMCC, and CTXR Headlines

Recent News About These Companies

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

July 29, 2025 | prnewswire.com

Virax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...

July 22, 2025 | finance.yahoo.com

Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 20, 2025 | finanznachrichten.de

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 18, 2025 | prnewswire.com

HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation

March 31, 2025 | msn.com

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

March 31, 2025 | benzinga.com

Virax Biolabs Launches Clinical Study on T Cell Dysfunction

March 18, 2025 | msn.com

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

March 18, 2025 | prnewswire.com

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

March 13, 2025 | prnewswire.com

Virax Biolabs to Present at 19th World Immune Regulation Meeting

March 5, 2025 | prnewswire.com

Virax Biolabs Aligns with US Health Department on Vaccine Transparency

February 25, 2025 | tipranks.com

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

February 25, 2025 | prnewswire.com

Cosmos Health expands distribution of Avian Influenza kits

January 23, 2025 | msn.com

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

January 23, 2025 | accessnewswire.comA

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

January 13, 2025 | accesswire.comA

Virax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?

December 19, 2024 | bovnews.comB

Virax Biolabs Announces Strategic Goals and Developments for 2025

December 18, 2024 | markets.businessinsider.com

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

December 17, 2024 | prnewswire.com

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

December 10, 2024 | prnewswire.com

Virax Biolabs Sees Asset Growth Amid Financial Loss

November 22, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, TXMD, IMCC, and CTXR Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.35 +0.12 (+9.76%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.26 -0.09 (-6.67%)

As of 08:29 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

IM Cannabis NASDAQ:IMCC

$2.36 +0.18 (+8.03%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$2.34 -0.02 (-0.64%)

As of 07:00 AM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

TherapeuticsMD NASDAQ:TXMD

$1.10 +0.02 (+1.84%)

Closing price 08/22/2025 03:55 PM Eastern

Extended Trading

$1.10 0.00 (-0.45%)

As of 08:00 AM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Virax Biolabs Group NASDAQ:VRAX

$0.76 +0.02 (+3.21%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$0.76 -0.01 (-0.65%)

As of 08:11 AM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time